Work

Bosutinib (BOS) vs Imatinib (IM) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Initial Results from the BFORE Trial

Year: 2017

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2017.07.117

Authors: Jorge Cortes, Carlo Gambacorti-Passerini, Michael Deininger, Michael Mauro, Charles Chuah, Dong Wook Kim, Laurence Reilly, Alison Jeynes-Ellis, Eric Leip, Nathalie Bardy-Bouxin, Andreas Hochhaus, Tim Brümmendorf

Institutions: The University of Texas MD Anderson Cancer Center, University of Milano-Bicocca, University of Utah, Memorial Sloan Kettering Cancer Center, Singapore General Hospital, Duke-NUS Medical School, The Catholic University of Korea Seoul St. Mary's Hospital, Avillion (United Kingdom), Pfizer (United States), Pfizer (France), Jena University Hospital, Universitätsklinikum Aachen, RWTH Aachen University

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2751266331

FWCI:

Cites:

Cited by: 1

Related to: 10